Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318930469> ?p ?o ?g. }
- W4318930469 endingPage "619" @default.
- W4318930469 startingPage "608" @default.
- W4318930469 abstract "Chondrosarcomas are well known for their resistance to conventional chemotherapy and radiotherapy treatment regimens, which is particularly detrimental in patients who have unresectable tumors. Recently, inhibition of poly(ADP-ribose) polymerase (PARP) by talazoparib was shown to sensitize chondrosarcoma cell lines to chemotherapy (temozolomide) or radiotherapy, irrespective of isocitrate dehydrogenase (IDH) mutation status. Because two-dimensionally grown cell lines have limitations and may not accurately represent the clinical response to drug treatment, we aimed to use a more representative three-dimensional alginate spheroid chondrosarcoma model. It is important to test therapeutic agents in vitro before testing them in animals or humans; therefore, we aimed to determine the effectiveness of a PARP inhibitor in reducing the viability of chondrosarcoma spheroids. Using a more stringent, complex in vitro model refines future therapeutic options for further investigation in animal models, increasing efficiency, reducing unnecessary animal use, and saving time and cost.(1) Does talazoparib treatment slow or inhibit the growth of chondrosarcoma spheroids, and does an increased treatment duration change the drug's effect? (2) Does talazoparib work in synergy with temozolomide treatment to reduce the viability of chondrosarcoma spheroids? (3) Does talazoparib work in synergy with radiotherapy treatment to reduce the viability of chondrosarcoma spheroids?Three representative conventional chondrosarcoma cell lines (CH2879 [IDH wildtype], JJ012 [IDH1 mutant], and SW1353 [IDH2 mutant]) were cultured as alginate spheroids and treated with talazoparib (0.001 to 10 µM), temozolomide (0.01 to 100 µM), or combinations of these drugs for 3, 7, and 14 days, representing different stages of spheroid growth. The cell lines were selected to represent a variety of IDH mutation statuses and were previously validated in spheroid culturing. Temozolomide was chosen because of its previous success when combined with PARP inhibitors, dissimilar to other commonly used chemotherapies. The effect on spheroid viability was assessed using three cell viability assays. Additionally, spheroid count, morphology, proliferation, and apoptosis were assessed. The effect of talazoparib (5 to 10 nM) combined with ƴ-radiation applied using a 137 C source (0 to 6 Gy) was assessed as surviving fractions by counting the number of spheroids (three). The therapeutic synergy of low-concentration talazoparib (5 to 10 nM) with temozolomide or radiotherapy was determined by calculating Excess over Bliss scores.Talazoparib treatment reduced the spheroid viability of all three cell lines after 14 days (IC 50 ± SD of CH2879: 0.1 ± 0.03 µM, fold change: 220; JJ012: 12 ± 1.4 µM, fold change: 4.8; and SW1353: 1.0 ± 0.2 µM, fold change: 154), compared with 3-day treatments of mature spheroids. After 14 days of treatment, the Excess over Bliss scores for 100 µM temozolomide and talazoparib indicated synergistic efficacy (Excess over Bliss scores: CH2879 59% [lower 95% CI 52%], JJ012 18% [lower 95% CI 8%], and SW1353 55% [lower 95% CI 25%]) of this combination treatment. A stable synergistic effect of talazoparib and radiotherapy was present only in JJ012 spheroids at a 4Gƴ radiation dose (Excess over Bliss score: 22% [lower 95% CI 6%]).In our study, long-term PARP inhibition was more effective than short-term treatment, and only one of the three chondrosarcoma spheroid lines was sensitive to combined PARP inhibition and radiotherapy. These findings suggest subsequent animal studies should focus on long-term PARP inhibition, and temozolomide combined with talazoparib has a higher chance of success than combination with radiotherapy.Combination treatment of talazoparib and temozolomide was effective in reducing the viability of chondrosarcoma spheroids and spheroid growth, regardless of IDH mutation status, providing rationale to replicate this treatment combination in an animal chondrosarcoma model." @default.
- W4318930469 created "2023-02-03" @default.
- W4318930469 creator A5035976720 @default.
- W4318930469 creator A5054542201 @default.
- W4318930469 creator A5064672264 @default.
- W4318930469 creator A5071512489 @default.
- W4318930469 creator A5072613641 @default.
- W4318930469 date "2022-12-13" @default.
- W4318930469 modified "2023-09-29" @default.
- W4318930469 title "Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model" @default.
- W4318930469 cites W1481822065 @default.
- W4318930469 cites W1606140785 @default.
- W4318930469 cites W1876426852 @default.
- W4318930469 cites W1985167677 @default.
- W4318930469 cites W1997349871 @default.
- W4318930469 cites W2005165035 @default.
- W4318930469 cites W2011376261 @default.
- W4318930469 cites W2023676537 @default.
- W4318930469 cites W2061404903 @default.
- W4318930469 cites W2076692938 @default.
- W4318930469 cites W2098217042 @default.
- W4318930469 cites W2115147179 @default.
- W4318930469 cites W2140590160 @default.
- W4318930469 cites W2154193486 @default.
- W4318930469 cites W2154451644 @default.
- W4318930469 cites W2346871801 @default.
- W4318930469 cites W2520107693 @default.
- W4318930469 cites W2585230893 @default.
- W4318930469 cites W2592941899 @default.
- W4318930469 cites W2783596779 @default.
- W4318930469 cites W2906986535 @default.
- W4318930469 cites W2947835913 @default.
- W4318930469 cites W2952481429 @default.
- W4318930469 cites W2952531582 @default.
- W4318930469 cites W2971539214 @default.
- W4318930469 cites W2983160271 @default.
- W4318930469 cites W2991465574 @default.
- W4318930469 cites W2996357887 @default.
- W4318930469 cites W3115335715 @default.
- W4318930469 cites W3117691224 @default.
- W4318930469 cites W3119609126 @default.
- W4318930469 cites W3132582417 @default.
- W4318930469 cites W3134901434 @default.
- W4318930469 cites W3134914296 @default.
- W4318930469 cites W4200505973 @default.
- W4318930469 doi "https://doi.org/10.1097/corr.0000000000002483" @default.
- W4318930469 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36729612" @default.
- W4318930469 hasPublicationYear "2022" @default.
- W4318930469 type Work @default.
- W4318930469 citedByCount "3" @default.
- W4318930469 countsByYear W43189304692023 @default.
- W4318930469 crossrefType "journal-article" @default.
- W4318930469 hasAuthorship W4318930469A5035976720 @default.
- W4318930469 hasAuthorship W4318930469A5054542201 @default.
- W4318930469 hasAuthorship W4318930469A5064672264 @default.
- W4318930469 hasAuthorship W4318930469A5071512489 @default.
- W4318930469 hasAuthorship W4318930469A5072613641 @default.
- W4318930469 hasBestOaLocation W43189304691 @default.
- W4318930469 hasConcept C126322002 @default.
- W4318930469 hasConcept C142724271 @default.
- W4318930469 hasConcept C143998085 @default.
- W4318930469 hasConcept C175369904 @default.
- W4318930469 hasConcept C181199279 @default.
- W4318930469 hasConcept C202751555 @default.
- W4318930469 hasConcept C2776302905 @default.
- W4318930469 hasConcept C2776694085 @default.
- W4318930469 hasConcept C2777150147 @default.
- W4318930469 hasConcept C2777389519 @default.
- W4318930469 hasConcept C502942594 @default.
- W4318930469 hasConcept C509974204 @default.
- W4318930469 hasConcept C53227056 @default.
- W4318930469 hasConcept C55493867 @default.
- W4318930469 hasConcept C71924100 @default.
- W4318930469 hasConcept C86803240 @default.
- W4318930469 hasConceptScore W4318930469C126322002 @default.
- W4318930469 hasConceptScore W4318930469C142724271 @default.
- W4318930469 hasConceptScore W4318930469C143998085 @default.
- W4318930469 hasConceptScore W4318930469C175369904 @default.
- W4318930469 hasConceptScore W4318930469C181199279 @default.
- W4318930469 hasConceptScore W4318930469C202751555 @default.
- W4318930469 hasConceptScore W4318930469C2776302905 @default.
- W4318930469 hasConceptScore W4318930469C2776694085 @default.
- W4318930469 hasConceptScore W4318930469C2777150147 @default.
- W4318930469 hasConceptScore W4318930469C2777389519 @default.
- W4318930469 hasConceptScore W4318930469C502942594 @default.
- W4318930469 hasConceptScore W4318930469C509974204 @default.
- W4318930469 hasConceptScore W4318930469C53227056 @default.
- W4318930469 hasConceptScore W4318930469C55493867 @default.
- W4318930469 hasConceptScore W4318930469C71924100 @default.
- W4318930469 hasConceptScore W4318930469C86803240 @default.
- W4318930469 hasIssue "3" @default.
- W4318930469 hasLocation W43189304691 @default.
- W4318930469 hasLocation W43189304692 @default.
- W4318930469 hasLocation W43189304693 @default.
- W4318930469 hasOpenAccess W4318930469 @default.
- W4318930469 hasPrimaryLocation W43189304691 @default.
- W4318930469 hasRelatedWork W1123018581 @default.
- W4318930469 hasRelatedWork W2073885660 @default.